ROIV
Roivant Sciences LtdNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$19.88B
P/E Ratio
—
EPS
$-1.17
Beta
1.21
52W High
$30.33
52W Low
$10.58
50-Day MA
$28.25
200-Day MA
$20.38
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Roivant Sciences Ltd
Roivant Sciences Ltd (ROIV) is an innovative biopharmaceutical company dedicated to revolutionizing drug development and commercialization through its unique business model and proprietary technologies. The company boasts a robust and diverse pipeline targeting significant unmet medical needs across neurology, immunology, and rare diseases, aiming to expedite the drug development process while minimizing costs. Roivant's experienced leadership team and strategic collaborations position it well to transform the healthcare landscape, offering compelling value propositions for investors and improving patient outcomes.
Fundamentals
| Revenue (TTM) | $13.31M |
| Gross Profit (TTM) | $-614.67M |
| EBITDA | $-1.26B |
| Operating Margin | -16965.00% |
| Return on Equity | -19.10% |
| Return on Assets | -14.50% |
| Revenue/Share (TTM) | $0.02 |
| Book Value | $6.02 |
| Price-to-Book | 4.67 |
| Price-to-Sales (TTM) | 1493.24 |
| EV/Revenue | 1165.38 |
| EV/EBITDA | 0.74 |
| Quarterly Earnings Growth (YoY) | -96.10% |
| Quarterly Revenue Growth (YoY) | -77.80% |
| Shares Outstanding | $715.70M |
| Float | $533.85M |
| % Insiders | 22.79% |
| % Institutions | 72.87% |
Historical Volatility
HV 10-Day
30.38%
HV 20-Day
31.37%
HV 30-Day
30.53%
HV 60-Day
53.15%
HV Rank
36.1%
Volatility is currently contracting
Analyst Ratings
Consensus ($35.67 target)
2
Strong Buy10
Buy1
HoldData last updated: 4/29/2026